Technical Analysis for ARNI - Arno Therapeutics

Grade Last Price % Change Price Change
F 0.0001 0.00% 0.0000
ARNI closed unchanged on Wednesday, September 20, 2023, on 11 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Flat

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Volume Surge Other 0.00%
Narrow Range Bar Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Arno Therapeutics Description

Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. was founded in 2005 and is based in Flemington, New Jersey.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biopharmaceutical Diseases Solid Tumors Treatment Of Cancer Cancer Treatment Amgen Treating Cancer Enones Hematological Malignancies Abortifacients Cancer Therapy Castration Resistant Prostate Cancer The Ohio State University University Of Minnesota

Is ARNI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.0021
52 Week Low 0.0001
Average Volume 8,843
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.0001
Average True Range 0.0000
RSI (14) 0.00
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs) N/A
Chandelier Exit (Short, 3 ATRs) N/A
Upper Bollinger Bands 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line 0.0000
MACD Signal Line 0.0000
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0001
Resistance 3 (R3) 0.0001 0.0001 0.0001
Resistance 2 (R2) 0.0001 0.0001 0.0001 0.0001
Resistance 1 (R1) 0.0001 0.0001 0.0001 0.0001 0.0001
Pivot Point 0.0001 0.0001 0.0001 0.0001 0.0001
Support 1 (S1) 0.0001 0.0001 0.0001 0.0001 0.0001
Support 2 (S2) 0.0001 0.0001 0.0001 0.0001
Support 3 (S3) 0.0001 0.0001 0.0001
Support 4 (S4) 0.0001